Xueying Chen1, Ziqing Yu1, Jin Bai1, Shulan Hu1,2, Wei Wang1, Shengmei Qin1, Jingfeng Wang1, Zhe Sun1, Yangang Su3, Junbo Ge1. 1. Shanghai Institution of Cardiovascular Disease, Department of Cardiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. 2. Department of Cardiology, Integrated Chinese and Western Medicine Hospital of Sanming, Sanming, Fujian Province, 365001, China. 3. Shanghai Institution of Cardiovascular Disease, Department of Cardiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. yangangsu@yeah.net.
Abstract
PURPOSE: The objective of the study is to study the incidence, significance, and factors associated with cardiac troponin T (CTNT) elevation after pacemaker implantation. METHODS: Three hundred seventy-four patients (104 single-chamber pacemakers or ICD, 243 dual-chamber pacemakers, and 27 cardiac resynchronization therapy/cardiac resynchronization therapy defibrillator) who had normal levels of CTNT at baseline and underwent implantation of a permanent pacemaker system were included in this study. Serum levels of CTNT were measured at baseline, 6 and 24 h after the implantation procedure. RESULTS: The median of CTNT levels increased from 0.012 ng/mL at baseline to 0.032 and 0.019 ng/mL at 6 and 24 h after the procedure, respectively (all p < 0.0001). Elevated CTNT levels were noted in 208 patients (55.6%) at 6 h after the implantation, among which 29 patients (7.8%) had CTNT levels exceeding the range of minimal myocardial damage (>0.09 ng/mL). After 1-year follow-up, the incidence of complications including dislodgement of the lead, pocket infection, pneumothorax, hemothorax, and vein thrombus and cardiac outcomes including hospitalization of heart failure, coronary artery disease, arrhythmia, and cardiovascular mortality was not significantly different between the normal and elevated CTNT groups at 6 h after the procedure. By logistic regression analysis, gender, N-terminal pro-B type natriuretic peptide (NT-pro-BNP) at baseline, left ventricular ejection fractions (LVEF), estimated glomerular filtration rate (eGFR), and fluoroscopy time were independently associated with CTNT elevation after adjusted for age, pacemaker types, right ventricle lead location (RVA or RVOT), heart function, and left ventricular end systolic dimension. CONCLUSIONS: Pacemaker implantation was found to be accompanied with CTNT elevation in 55.6% of the patients at 6 h after the procedure, and its kinetics were fast, which might not be related to the complications and adverse cardiac outcomes within 1 year of follow-up. Moreover, gender, NT-pro-BNP at baseline, LVEF, eGFR, and fluoroscopy time were found to be independent predictors of CTNT elevation.
PURPOSE: The objective of the study is to study the incidence, significance, and factors associated with cardiac troponin T (CTNT) elevation after pacemaker implantation. METHODS: Three hundred seventy-four patients (104 single-chamber pacemakers or ICD, 243 dual-chamber pacemakers, and 27 cardiac resynchronization therapy/cardiac resynchronization therapy defibrillator) who had normal levels of CTNT at baseline and underwent implantation of a permanent pacemaker system were included in this study. Serum levels of CTNT were measured at baseline, 6 and 24 h after the implantation procedure. RESULTS: The median of CTNT levels increased from 0.012 ng/mL at baseline to 0.032 and 0.019 ng/mL at 6 and 24 h after the procedure, respectively (all p < 0.0001). Elevated CTNT levels were noted in 208 patients (55.6%) at 6 h after the implantation, among which 29 patients (7.8%) had CTNT levels exceeding the range of minimal myocardial damage (>0.09 ng/mL). After 1-year follow-up, the incidence of complications including dislodgement of the lead, pocket infection, pneumothorax, hemothorax, and vein thrombus and cardiac outcomes including hospitalization of heart failure, coronary artery disease, arrhythmia, and cardiovascular mortality was not significantly different between the normal and elevated CTNT groups at 6 h after the procedure. By logistic regression analysis, gender, N-terminal pro-B type natriuretic peptide (NT-pro-BNP) at baseline, left ventricular ejection fractions (LVEF), estimated glomerular filtration rate (eGFR), and fluoroscopy time were independently associated with CTNT elevation after adjusted for age, pacemaker types, right ventricle lead location (RVA or RVOT), heart function, and left ventricular end systolic dimension. CONCLUSIONS: Pacemaker implantation was found to be accompanied with CTNT elevation in 55.6% of the patients at 6 h after the procedure, and its kinetics were fast, which might not be related to the complications and adverse cardiac outcomes within 1 year of follow-up. Moreover, gender, NT-pro-BNP at baseline, LVEF, eGFR, and fluoroscopy time were found to be independent predictors of CTNT elevation.
Authors: Nikolaos I Nikolaou; Apostolos H Christou; Stavros G Spanodimos; Dionysios G Antonatos; Panagiotis I Korkonikitas; Sotirios P Patsilinakos Journal: Hellenic J Cardiol Date: 2011 Nov-Dec
Authors: Franck Maziere; Sophie Birolleau; Sassi Medimagh; Martine Arthaud; Mohamed Bennaceur; Bruno Riou; Patrick Ray Journal: Eur J Emerg Med Date: 2007-08 Impact factor: 2.799
Authors: Remy J H Martens; Dorien M Kimenai; Jeroen P Kooman; Coen D A Stehouwer; Frans E S Tan; Otto Bekers; Pieter C Dagnelie; Carla J H van der Kallen; Abraham A Kroon; Karel M L Leunissen; Frank M van der Sande; Nicolaas C Schaper; Simone J S Sep; Miranda T Schram; Jeroen D van Suijlen; Marja P van Dieijen-Visser; Steven J R Meex; Ronald M A Henry Journal: Clin Chem Date: 2017-02-17 Impact factor: 8.327
Authors: Nikolaos I Nikolaou; Stavros G Spanodimos; Elias P Tsaglis; Dionysios G Antonatos; Sotiris P Patsilinakos; Georgios M Fournarakis; Dimitrios L Tsigas Journal: Pacing Clin Electrophysiol Date: 2005-11 Impact factor: 1.976
Authors: Lesley A Stevens; Suying Li; Manjula Kurella Tamura; Shu-Cheng Chen; Joseph A Vassalotti; Keith C Norris; Adam T Whaley-Connell; George L Bakris; Peter A McCullough Journal: Am J Kidney Dis Date: 2011-03 Impact factor: 8.860
Authors: Tomas Hnatek; Milos Taborsky; Martin Maly; Libor Kamenik; Simona Littnerova; Pavel Sedlon; Jana Luxova; Marta Fiserova; Lenka Pospisilova; Sarka Hamouzova; Josef Danek; Miroslav Zavoral Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2016-01-13 Impact factor: 1.245
Authors: Christopher deFilippi; Stephen L Seliger; Walter Kelley; Show-Hong Duh; Michael Hise; Robert H Christenson; Myles Wolf; Hanna Gaggin; James Januzzi Journal: Clin Chem Date: 2012-07-12 Impact factor: 8.327
Authors: Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983